🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I received a $125.00 donation supporting Dolphins Challenge Cancer! dolphins.donordrive.com/index.cfm?fuse…

March is Multiple Myeloma Awareness Month! This week, we had full program in Coral Gables. The coming weeks, we will have great programs in downtown Miami and in Deerfield. Don’t miss these events! #mmsm International Myeloma Foundation Multiple Myeloma RF HealthTree Foundation Sylvester Comprehensive Cancer Center #miami University of Miami

Happening Now!

The evolution of response assessment in MM Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 C. Ola Landgren, M.D. Ben Diamond, MD

How can we monitor MRD often given need of bone marrow biopsies? Blood based mass spec?

Where have we or currently in for RRMM treatment #immunotherapy with Ken Shain. C. Ola Landgren, M.D.

Former Artsakh State Minister, businessman, and philanthropist Ruben Vardanyan has been nominated for the 2024 Nobel Peace Prize for his charitable and humanitarian work. His candidacy was proposed by several influential individuals, including a Nobel Peace Prize laureate. The

In a ‘Historical’ Moment FDA Committee Rules on a Faster Way to Approve Therapies for Myeloma Honored to present EVIDENCE meta-analysis, work I pioneered 15 yrs ago. Congrats also to I2TEAMM International Myeloma Foundation Multiple Myeloma RF #mmsm HealthTree Foundation ⁦Sylvester Comprehensive Cancer Center⁩ news.med.miami.edu/multiple-myelo…

#mmsm Multiple Myeloma RF With MRD as early endpoint for accelerated approval of new multiple myeloma drugs, patients' access to new therapies will be much quicker. Instead of waiting for 10-15 yrs, new drugs can be available in 3-5 yrs. Here is how it works: vjhemonc.com/video/mzdrxxne…

and here's a link to our previous medRxiv tweetorial if you want the key points: x.com/BenDiamondMD/s…

Clearing the path for MRD as early endpoint in multiple myeloma. Conversation with C. Ola Landgren, M.D. of Sylvester Comprehensive Cancer Center. cancerletter.com/conversation-w…

IsaVRD. More is better. For TI NDMM <80yo. C. Ola Landgren, M.D. Sylvester Comprehensive Cancer Center OncoDaily

ANCA Congressional Endorsements 2024 anca.org/anca-congressi…

This is Robert F. Kennedy Jr - under consideration today for a cabinet level post - demanding justice for the Armenian nation, the return of Armenians to Artsakh.

dolphinscancerchallenge.com/participant/43… Consider supporting me and Team Myeloma for the DCC fundraising cancer challenge.

One week left. Thank you for supporting Sylvester and our myeloma institute

And that's a wrap on #MyelomaMRD2025! We just heard from Ben Diamond, MD, David Coffey & Hans Lee (MD Anderson Cancer Center), who highlighted exciting new MRD technologies emerging in myeloma! Sylvester Comprehensive Cancer Center #mmMRD #MMsm

Topline results for ADVANCE: Dara-KRd vs KRd MRD <10^-5 higher with Dara-KRd - The scale for PFS is adjusted here to accentuate differences, but we don't see a difference...at least not yet. - Don't know how many patients went to ASCT in either arm (more in KRd arm?) -

ICYMI: In newly diagnosed multiple myeloma (NDMM), the addition of daratumumab (D) to the KRd regimen significantly improved minimal residual disease (MRD) negativity. In the ADVANCE clinical trial (NCT04268498), 306 patients received either DKRd or KRd for 8 cycles. Results